, /PRNewswire/ -- (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, will present key findings from their CNS-101 study at the in . The study was conducted in collaboration with the . Two posters were accepted by the AAIC Scientific Program Committee for presentation at the Technology and Dementia Preconference and the main meeting.
Additionally, one poster was selected for presentation at the Technology and Dementia Preconference Data Blitz. Cumulus poster presentation details are as follows: "Traditional measures used in Alzheimer's clinical studies lack objectivity, do not scale to support large real-world studies, and require patients to attend clinic appointments which can be highly stressful, impacting results," said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. "Importantly, these measures do not provide a clear picture regarding neurological health in a patient's day-to-day life.
We need scalable digital biomarkers that enable objective, longitudinal measurement of brain function in a real-world setting. We look forward to sharing results from our CNS-101 study at AAIC 2024. We are deeply grateful to all the study participants and collaborators who have dedicated their careers to better understanding this devastating neurodegenerative disease with the hope of accelerating the development of much needed therapies.
" Alzheimer's is a progressive disease th.
